Press Releases

Date Title  
Toggle Summary Natera Announces Pricing of Follow-On Offering
SAN CARLOS, Calif. , Oct. 16, 2019 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,714,286 shares of its common stock at a price to the public of $35.00 per share.
Toggle Summary Natera Launches Proposed Follow-On Offering
SAN CARLOS, Calif. , Oct. 15, 2019 /PRNewswire/ -- Natera, Inc . (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $175,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day
Toggle Summary Natera to Host Investor Conference Call to Discuss Progress in its Oncology Business
  SAN CARLOS, Calif. , Oct. 3, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced it will review recent progress in its oncology business, including the positive draft local coverage decision for Signatera ™ in colorectal cancer and
Toggle Summary Foundation Medicine and Natera Partner to Advance Personalized Cancer Monitoring
  CAMBRIDGE, Mass. and SAN CARLOS, Calif. , Sept. 25, 2019 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA) today announced a partnership to develop and commercialize personalized circulating tumor DNA (ctDNA) monitoring assays, for use by biopharmaceutical and clinical
Toggle Summary CBR to Acquire Natera's Evercord™ Cord Blood Business
Sharpens Natera's Focus on Reproductive Health, Oncology and Organ Transplant SAN CARLOS, Calif. , Sept. 13, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) and   CBR (Cord Blood Registry )  today announced the acquisition by CBR, a California Cryobank Life Sciences company, and the world's
Toggle Summary Natera Publishes Largest NIPT Outcomes Study Demonstrating Robust Clinical Performance Over a 4-year Period
High positive predictive value shown for common chromosomal aneuploidies in all women, including women under 35 years of age SAN CARLOS, Calif. , Sept. 9, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of the largest
Toggle Summary Natera to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
SAN CARLOS, Calif. , Sept. 4, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 17th Annual Global Healthcare Conference at the Grand Hyatt New York on Wednesday, Sept.
Toggle Summary Natera Appoints Rowan Chapman to its Board of Directors
SAN CARLOS, Calif. , Aug. 29, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has appointed Rowan Chapman , Ph.D., to its board of directors, effective August 15, 2019 . "We are extremely pleased to welcome Dr.
Toggle Summary Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference
SAN CARLOS, Calif. , Aug. 28, 2019 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Baird 2019 Global Healthcare Conference at the InterContinental New York Barclay hotel in New York City on Wednesday,
Toggle Summary Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera™ MRD Test in Colorectal Cancer
First step towards reimbursement and adoption of MRD testing in solid tumors SAN CARLOS, Calif. , Aug. 22, 2019 /PRNewswire/ -- Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the Palmetto MolDX program has proposed a local coverage determination (LCD)

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.